Guidance on the use of imatinib for chronic myeloid leukaemia
National Institute for Clinical Excellence
Record ID 32003000008
English
Authors' objectives:
To provide guidance on the use of imatinib for chronic myeloid leukaemia.
Authors' recommendations:
Guidance: 1.1 Imatinib is recommended as a treatment option for the management of Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in chronic phase in adults who are intolerant of interferon-alpha (IFN-alpha) therapy or in whom IFN-alpha is deemed to have failed to control the disease.
1.2 IFN-alpha failure is defined as either: - failure to achieve complete haematological response after 3 months of IFN-alpha treatment as monotherapy or in combination with hydroxyurea, or - failure to achieve major cytogenetic response after 1 year of IFN-alpha treatment despite haematological response. IFN-alpha intolerance is defined as the presence of documented Grade 3 non-haematological toxicity, persisting for more than 2 weeks, in a patient receiving a regimen that contains IFN-alpha.
1.3 Imatinib is recommended as an option for the treatment of adults with Philadelphia-chromosome-positive CML in accelerated phase or blast crisis provided they have not received imatinib treatment at an earlier stage.
Authors' methods:
Systematic review
Details
Project Status:
Completed
URL for project:
http://www.nice.org.uk/cat.asp?c=37604
Year Published:
2002
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Contact
Organisation Name:
National Institute for Clinical Excellence
Contact Address:
MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.